

TREATMENT PERSPECTIVES

Are your patients aware of their shingles risk?

Test your knowledge of shingles

Question

The incidence of shingles sharply increases starting at what age?¹

YOUR ANSWER:

- A. 50 years old
- B. 20 years old
- C. 30 years old
- D. 70 years old

[Test your knowledge again](#)

[Click here to learn more about SHINGRIX for your patients](#)

Indication

SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX

Indication

SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
- In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
- Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
- Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
- Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)
- The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
- It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Please see full **Prescribing Information** for SHINGRIX.

TREATMENT PERSPECTIVES

Are your patients aware of their shingles risk?

Test your knowledge of shingles

Question

The incidence of shingles sharply increases starting at what age?¹

YOUR ANSWER:

- A. 50 years old
- B. 20 years old
- C. 30 years old
- D. 70 years old

Indication

SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
- In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
- Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
- Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
- Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)
- The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
- It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Please see full [Prescribing Information](#) for SHINGRIX.

References:

1. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2008;57(RR-5):1-30.
2. Prescribing Information for SHINGRIX.
3. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. *J Med Virol*. 2003;70(suppl 1):S111-S118.



Treatment Perspectives is a trademark of Relevate Health Group, LLC. All other trademarks are owned by or licensed to the GSK group of companies.

©2024 GSK or licensor.
PMUS-SGXWCNT240022 June 2024
Produced in USA.

[Contact Us](#) [Privacy Statement](#) [Legal Notices](#)

The site is published by Relevate Health, and is intended for healthcare professionals in the United States only.
Your use of information on the site and your registration for services and events offered through this site are subject to the Relevate Health [Terms of Use](#) and its [Privacy Policy](#).
[Do Not Sell My Personal Information](#) | 1-877-238-8500

Relevate Health, 3825 Edwards Road, Suite 610, Cincinnati, OH 45209


TREATMENT PERSPECTIVES

Are your patients aware of their shingles risk?

Test your knowledge of shingles

QuestionThe incidence of shingles sharply increases starting at what age?¹**YOUR ANSWER:**

- A. 50 years old
 B. 20 years old
 C. 30 years old
 D. 70 years old

[Test your knowledge again](#)[Click here to learn more about SHINGRIX for your patients](#)**CORRECT ANSWER IS:****A.** The incidence of shingles sharply increases starting at 50 years old.¹Incidence rate* of zoster by age—United States¹**SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults ≥50 years old.²****YOUR PATIENTS ≥50 YEARS OLD ARE AT RISK FOR SHINGLES, NO MATTER HOW HEALTHY THEY MAY FEEL^{1,3}**

99.5%
OF PEOPLE ≥50 YEARS
OLD ARE INFECTED
with the varicella zoster virus.^{1,3}

In 1 out of 3 people, the dormant virus reactivates in their lifetime and causes shingles.¹

*Per 1000 person-years.

Learn more about the impact of shingles [here](#).**Indication**

SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
- In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
- Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
- Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
- Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)
- The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
- It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Please see full [Prescribing Information](#) for SHINGRIX.**References:**

1. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2008;57(RR-5):1-30.
2. Prescribing Information for SHINGRIX.
3. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. *J Med Virol*. 2003;70(suppl 1):S111-S118.

GSK

Treatment Perspectives is a trademark of Relevance Health Group, LLC. All other trademarks are owned by or licensed to the GSK group of companies.

©2024 GSK or licensor.
PMUS-SGXWCNT240022 June 2024
Produced in USA.

[Contact Us](#) [Privacy Statement](#) [Legal Notices](#)

The site is published by Relevance Health, and is intended for healthcare professionals in the United States only. Your use of information on the site and your registration for services and events offered through this site are subject to the Relevance Health [Terms of Use](#) and its [Privacy Policy](#).
[Do Not Sell My Personal Information](#) | 1-877-238-8500

Relevance Health, 3825 Edwards Road, Suite 610, Cincinnati, OH 45209

This website is funded and developed by GSK.

Prescribing Information

This website is intended for US healthcare professionals only.

TREATMENT PERSPECTIVES

Are your patients aware of their shingles risk?

Test your knowledge of shingles

Question

The incidence of shingles sharply increases starting at what age?¹

YOUR ANSWER:

- A. 50 years old
- B. 20 years old
- C. 30 years old
- D. 70 years old

Indication

SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX

This website is funded and developed by GSK.

Prescribing Information

This website is intended for US healthcare professionals only.

Indication

SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
- In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
- Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
- Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
- Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)
- The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
- It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Please see full [Prescribing Information](#) for SHINGRIX.

Prescribing Information

This website is intended for US healthcare professionals only.

TREATMENT PERSPECTIVES

Are your patients aware of their shingles risk?

Test your knowledge of shingles

Question

The incidence of shingles sharply increases starting at what age?¹

YOUR ANSWER:

- A. 50 years old
- B. 20 years old
- C. 30 years old
- D. 70 years old

Indication

SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
- In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
- Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
- Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
- Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)
- The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
- It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Please see full [Prescribing Information](#) for SHINGRIX.

References:

1. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2008;57(RR-5):1-30.
2. Prescribing Information for SHINGRIX.
3. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. *J Med Virol*. 2003;70(suppl 1):S111-S118.



Treatment Perspectives is a trademark of Relevate Health Group, LLC. All other trademarks are owned by or licensed to the GSK group of companies.

©2024 GSK or licensor.
PMUS-SGXWCNT240022 June 2024
Produced in USA.

[Contact Us](#) [Privacy Statement](#) [Legal Notices](#)

The site is published by Relevate Health, and is intended for healthcare professionals in the United States only.

Your use of information on the site and your registration for services and events offered through this site are subject to the Relevate Health [Terms of Use](#) and its [Privacy Policy](#).

[Do Not Sell My Personal Information](#) | 1-877-238-8500

Relevate Health, 3825 Edwards Road, Suite 610, Cincinnati, OH 45209

This website is funded and developed by GSK.

Prescribing Information

This website is intended for US healthcare professionals only.

TREATMENT PERSPECTIVES

Are your patients aware of their shingles risk?

Test your knowledge of shingles

Question

The incidence of shingles sharply increases starting at what age?¹


YOUR ANSWER:

- A. 50 years old
- B. 20 years old
- C. 30 years old
- D. 70 years old

CORRECT ANSWER IS:

A. The incidence of shingles sharply increases starting at 50 years old.¹

Incidence rate* of zoster by age—United States¹



*Per 1000 person-years.¹

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults ≥50 years old.²

YOUR PATIENTS ≥50 YEARS OLD ARE AT RISK FOR SHINGLES, NO MATTER HOW HEALTHY THEY MAY FEEL^{1,3}

99.5%

OF PEOPLE ≥50 YEARS OLD ARE INFECTED

with the varicella zoster virus.^{1,3}

In 1 out of 3 people, the dormant virus reactivates in their lifetime and causes shingles.¹

*Per 1000 person-years.

Learn more about the impact of shingles [here](#).

Test your knowledge again

[Click here to learn more about SHINGRIX for your patients](#)

Indication

SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).


Important Safety Information

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
- In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
- Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
- Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
- Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)
- The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
- It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Please see full [Prescribing Information](#) for SHINGRIX.

References:

1. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2008;57(RR-5):1-30.
2. Prescribing Information for SHINGRIX.
3. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. *J Med Virol*. 2003;70(suppl 1):S111-S118.



Treatment Perspectives is a trademark of Relevate Health Group, LLC. All other trademarks are owned by or licensed to the GSK group of companies.

©2024 GSK or licensor.
PMUS-SGXWCNT240022 June 2024
Produced in USA.

[Contact Us](#) [Privacy Statement](#) [Legal Notices](#)

The site is published by Relevate Health, and is intended for healthcare professionals in the United States only. Your use of information on the site and your registration for services and events offered through this site are subject to the Relevate Health [Terms of Use](#) and its [Privacy Policy](#).
[Do Not Sell My Personal Information](#) | 1-877-238-8500

Relevate Health, 3825 Edwards Road, Suite 610, Cincinnati, OH 45209